AN2 Therapeutics Inc. (ANTX)
NASDAQ: ANTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
ANTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $183.02M
- EPS (TTM)
- -$1.05
- Dividend yield
- None
- 52-week range
- 1.00 – 7.19
- Day range
- 4.70 – 5.06
- Volume / Avg
- 365.10K / 237.78K
- Beta
- —
- Shares outstanding
- 37.74M
52-week range
ANTX stock today
AN2 Therapeutics (ANTX) closed at $4.85 on Oct 7, down 4.34% (-$0.22), versus the S&P 500's 0.22% decline. Shares are 32.5% below their 52-week high of $7.19, set on Aug 12, 2026 and 385.0% above the 52-week low of $1.00, in the middle of the past year's range. ANTX is up 325.4% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 270.2%.
AN2 Therapeutics has posted a net loss over the last twelve months (EPS of -$1.05), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About AN2 Therapeutics
Company profileAN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Eric E. Easom
- Headquarters
- Menlo Park, CA
- Employees
- 21
- IPO year
- 2022
- Website
- an2therapeutics.com
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$9.00+85.57%
- Strong buy 0
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
AN2 Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ORMPOramed Pharmaceuticals Inc. | 4.37 | -0.23% | $181.78M | vs ANTX |
| ADCTADC Therapeutics SA | 1.42 | +11.81% | $181.29M | vs ANTX |
| CNTNCanton Strategic Holdings Inc. | 2.26 | -3.42% | $180.08M | vs ANTX |
| NGENNervGen Pharma Corp. | 1.74 | -0.57% | $187.09M | vs ANTX |
| ADAGAdagene Inc. ADR | 2.81 | -4.10% | $188.67M | vs ANTX |
| YARWYarrow Bioscience Inc. | 18.78 | +0.24% | $174.69M | vs ANTX |
| WHWKWhitehawk Therapeutics Inc. | 3.41 | -5.54% | $194.40M | vs ANTX |
| ORGOOrganogenesis Holdings Inc. Class A | 1.32 | -1.49% | $169.85M | vs ANTX |
Indexes, lists and sector
AN2 Therapeutics stock FAQ
What is AN2 Therapeutics's stock price today?
ANTX last traded at $4.85 as of Oct 7, 4:00 PM EDT, down 4.34% on the day. Prices are delayed at least 15 minutes.
Who is AN2 Therapeutics's CEO?
Mr. Eric E. Easom is the chief executive officer of AN2 Therapeutics Inc., which has about 21 employees.
What is the ANTX 52-week high?
The 52-week high for ANTX is $7.19 and the 52-week low is $1.00. The stock is currently 32.5% below its high.